Results 31 to 40 of about 192,514 (206)

An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo

Vaccines, 2021
The mRNA-based vaccine approach is a promising alternative to traditional vaccines due to its ability for prompt development, high potency, and potential for secure administration and low-cost production.
Md. Motiar Rahman, Nan Zhou, Jiandong Huang   +2 more
doaj   +1 more source

Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain [PDF]

, 2012
Segment 7 of influenza A virus produces up to four mRNAs. Unspliced transcripts encode M1, spliced mRNA2 encodes the M2 ion channel, while protein products from spliced mRNAs 3 and 4 have not previously been identified.
Digard, Paul, Firth, Andrew E., Fodor, Ervin, Gog, Julia R., Hutchinson, Edward C., Jagger, Brett W., Kang, Zi H., Kash, John C., Robb, Nicole, Schwartzman, Louis M., Stuart, Amanda D., Taubenberger, Jeffery K., Wise, Helen M.   +12 more
core   +4 more sources

Recent Updates on mRNA Vaccines

Vaccines, 2022
Messenger RNA has been studied by everyone, from vaccine developers to high school biology students, since the discovery of its isolation in 1961 [...]
Emily Sydow, Abu Salim Mustafa, Asma Hanif, Javed Tunio, Shumaila Nida Muhammad Hanif   +4 more
openaire   +3 more sources

Deletion of parasite immune modulatory sequences combined with immune activating signals enhances vaccine mediated protection against filarial nematodes [PDF]

, 2012
<p>Background: Filarial nematodes are tissue-dwelling parasites that can be killed by Th2-driven immune effectors, but that have evolved to withstand immune attack and establish chronic infections by suppressing host immunity. As a consequence, the
AB Fredriksen, AB Pedersen, AE O'Connell, AE Schwab, B de Andres, B Manoury, BL Makepeace, BW Li, C Klotz, C Martin, C Martin, D Abraham, D Abraham, D Horst, D Knox, David W. Taylor, DH Barouch, DL Redmond, E Maraskovsky, G Ahlen, G Nchinda, GT Joseph, HA Farid, HongLin Luo, J Gardon, J Murray, JE Allen, JE Allen, JJ Donnelly, JP Hewitson, Judith E. Allen, KJ Fairlie-Clarke, KJ Ishii, LM Mir, LM Mir, LvG Jørgensen, MD Taylor, MD Taylor, MY Osei-Atweneboana, N Gomez-Escobar, Nick Gray, O Golden, PJ Hotez, R Ihaka, RM Maizels, RT Rwegoshora, S Babayan, S Frontier, S Mendez, S Ramachandran, S Thirugnanam, SA Babayan, SA Babayan, SB Anand, SB Anand, SB Anand, Simon A. Babayan, SM Sumida, Stephen John Davies, W Harnett, WF Gregory, WF Gregory, Y Dash, Y Wu   +63 more
core   +9 more sources

Cytokines of Birds: Conserved Functions [PDF]

, 2001
Targeted disruptions of the mouse genes for cytokines, cytokine receptors, or components of cytokine signaling cascades convincingly revealed the important roles of these molecules in immunologic processes. Cytokines are used at present as drugs to fight
Göbel, Thomas W. F., Kaspers, Bernd, Puehler, Florian, Schneider, Kirsten, Staeheli, Peter   +4 more
core   +1 more source

Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain

Pharmaceutics, 2022
The vaccine distribution chains in several low- and middle-income countries are not adequate to facilitate the rapid delivery of high volumes of thermosensitive COVID-19 mRNA vaccines at the required low and ultra-low temperatures. COVID-19 mRNA vaccines
Zoltán Kis
doaj   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Vaccines, 2023
Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who had ...
Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Thiti Susiriwatananont, Nicha Zungsontiporn, Nussara Pakvisal   +10 more
doaj   +1 more source

Immunogenicity of targeted lentivectors [PDF]

, 2014
To increase the safety and possibly efficacy of HIV-1 derived lentivectors (LVs) as an anti-cancer vaccine, we recently developed the Nanobody (Nb) display technology to target LVs to antigen presenting cells (APCs).
Adotévi, Bennett, Bevan, Bhardwaj, Bhardwaj, Bhardwaj, Blander, Bonehill, Bonehill, Breckpot, Breckpot, Breckpot, Charleston, Chuah, Collins, Collins, Collins, Collins, Cosset, Diebold, Donckier, Eggermont, Enk, Figdor, Gajewski, Garcia, Groettrup, Inaba, Kast, Lahoutte, Lévy, McCullough, Medzhitov, Melief, Mellman, Mortha, Moser, Moser, Munn, Naldini, Neyns, Noguiez-Hellin, Nussenzweig, Palena, Raes, Reis e Sousa, Reiser, Reiser, Richardson, Romani, Roncarolo, Sakuma, Schroyens, Semesyuk, Song, Storm, Thielemans, Thielemans, Thielemans, Thielemans, Torretta, Turk, Van Kooyk, Wang, Wang, Yamaguchi, Yewdell, Yu   +67 more
core   +3 more sources

mRNA vaccines for cancer immunotherapy

Frontiers in Immunology, 2022
Immunotherapy has emerged as a breakthrough strategy in cancer treatment. mRNA vaccines are an attractive and powerful immunotherapeutic platform against cancer because of their high potency, specificity, versatility, rapid and large-scale development capability, low-cost manufacturing potential, and safety.
Yashavantha L. Vishweshwaraiah, Nikolay V. Dokholyan, Nikolay V. Dokholyan, Nikolay V. Dokholyan, Nikolay V. Dokholyan   +4 more
openaire   +3 more sources